SottoPelle vs Biote: What Actually Differs Between These Hormone Pellet Systems

SottoPelle vs Biote is not a clean product-versus-product contest. Both are clinic training and support systems used for custom-compounded hormone pellet therapy, but the exact pharmacy, formulation, dose, and follow-up can differ. Biote discloses more of its supply chain; SottoPelle names its dosing system. Neither has proven superiority, and neither publishes a national patient price.

By The HRT Index Editorial Team · Published August 2026 · Last verified August 2026

Editorial research. Not medical advice. Not reviewed by a clinician.

The question is not just which logo looks better on a clinic wall. It is whether you can identify who made the thing going under your skin, what is in it, how many milligrams you are getting, what it will really cost, and what happens if the dose is wrong.

That became impossible to treat as a theoretical concern in January 2026. Asteria Health, the 503B outsourcing facility Biote owns, recalled specific hormone-pellet lots because of potential metal particulate matter. Biote notified affected practitioners. We found no public patient press release from Biote. Whether an individual patient heard about the recall therefore depended on what her clinic did next.^[1]

And here is the damaging admission up front: Biote is easier to criticize because it is easier to investigate. Its public filings identify its primary pellet facilities and disclose the recall. SottoPelle's public materials say its pellets come from a 503B outsourcing facility, but we could not find the facility's name. Transparency is what makes the transparent company look worse.

Best for / not for you if

A SottoPelle-certified clinic may fit you better if: the local clinician is the stronger clinician, will name the exact 503B facility and lot, can explain how the Dosaggio-informed dose was chosen, and gives you a written all-in cost and follow-up plan.

A Biote-certified clinic may fit you better if: the local clinician is the stronger clinician and you value a supply chain you can partly verify in public filings. You still need to ask which facility made your pellet because Biote-certified practitioners can use more than one facility.

Neither route is a good fit if: you need to lower or stop the dose within days · you need a medication your insurance reliably covers · you have a uterus and no written uterine-lining protection plan for systemic estrogen · or you have not discussed adjustable, FDA-approved routes with a clinician first.

The 60-second verdict

No head-to-head trial establishes a SottoPelle or Biote winner. Biote offers more public supply-chain disclosure and a much larger company-reported U.S. clinic footprint; SottoPelle offers a named patented dosing platform and a longer heritage claim. The decision that changes your risk is not the certificate. It is the clinician, exact pharmacy, lot, dose, follow-up, and written complication plan.

Decision fact	SottoPelle	Biote
What it is	Private clinician-training and support system	Public company that trains and supports clinicians and owns a 503B manufacturer
Founded / history	Company materials trace the method to Gino Tutera's work beginning in the early 1990s	Founded in 2012
Who makes the pellet	Public materials checked through August 25, 2026 describe a 503B outsourcing facility but do not name it	Three primary 503B facilities named in the 2025 Form 10-K: Asteria Health, AnazaoHealth, and Right Value Drug Stores LLC, doing business as Carie Boyd's Prescription Shop
Can the brand alone identify your manufacturer?	No	No — practitioners may use other facilities, and the three primary facilities are not interchangeable
FDA-approved finished pellet?	No — custom-compounded	No — custom-compounded
Dosing support	Dosaggio, described by SottoPelle as its patented dosing platform	Proprietary algorithm and clinical decision-support software
Public network data	Conflicting scopes: 1,200+ trained and certified worldwide, 3,000+ trained across the U.S., and 3,500+ trained over time	Company-reported 9,200+ providers in 5,300+ clinics as of December 31, 2025
2026 recall	No recall found under the SottoPelle or Tutera Medical names; supplier-level checking remains unresolved without the supplier name	Specific Asteria Health lots recalled in January 2026
National patient price	Not published	Not published
Head-to-head SottoPelle vs Biote study	None found	None found

The honest bottom line: this page cannot give you a scientifically proven brand winner because one does not exist. What it can give you is the evidence that exposes a weak clinic before you pay.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

SottoPelle vs Biote: what's the bottom line?

SottoPelle and Biote are not two standardized, FDA-approved drugs waiting to be compared by brand. They are clinician-training and support systems used around custom-compounded hormone pellets. No published head-to-head trial establishes one as safer, more effective, or more consistent. The brand narrows the system; it does not settle the medicine or the care.

Here is the thing almost every comparison page gets wrong—usually because a clean winner is easier to sell.

You think you are choosing between two products. You are not. You are choosing between two certificates on a wall. Under each certificate sits a local clinician, a compounding facility, a formulation, a lot number, a dose, an insertion technique, a monitoring plan, and a policy for what happens when things do not go smoothly.

That does not mean the brands are meaningless. Biote's public-company filings create a level of supply-chain visibility that SottoPelle's public materials do not. SottoPelle's Dosaggio platform and training format are real system differences. Biote's network scale is a real access difference. The 2026 Asteria recall is a real manufacturing event.

It means the brand is only the beginning of the question.

Biote's own Form 10-K makes that plain. It says its certified practitioners can use a variety of outsourcing facilities and that Biote does not control or direct compounding at the two named facilities it does not own.^[2] SottoPelle's training page likewise says clinicians receive a choice of pellet provider.^[3]

So when a clinic says its brand is “the safe one,” ask for the pharmacy and lot. When it says its dosing system is “more precise,” ask for the milligrams and the published comparative outcome data. When it says its pellets “last longer,” ask whether that claim applies to your exact formulation and dose.

A certificate is not a lot number. A logo is not a dose. And neither one is a substitute for a clinician who can answer direct questions without flinching.

---

What are SottoPelle and Biote, actually?

SottoPelle and Biote train clinicians, provide dosing and practice-support systems, and connect clinics with pellet supply options. The clinician who evaluates, prescribes, inserts, and follows you remains responsible for medical care. That matters because consultation depth, formulation, dosing, uterine protection, monitoring, insertion skill, and complication response can vary inside either brand.

SottoPelle

SottoPelle's current clinician materials describe a one-day certification program with required training modules, separate male and female insertion modules, online or in-person options, and access to Dosaggio, its patented dosing platform.^[3] The company says it has trained more than 3,500 HRT providers over time.^[4]

Its pitch is heritage and individualization. The public materials connect the method to Gino Tutera and say Dosaggio was built in 2006. What the public materials do not establish is that Dosaggio produces better outcomes than Biote's system, an FDA-approved route, or an experienced clinician using another protocol. A patented calculator is a tool. It is not a head-to-head clinical result.

SottoPelle also markets the program to clinicians as a practice-growth decision. That is not hidden. Its provider materials talk about revenue, patient retention, and expanding a practice.

Biote

Biote was founded in 2012 and is publicly traded. Its 2025 Form 10-K says that, as of December 31, 2025, more than 9,200 providers in more than 5,300 clinics had completed its curriculum and training. It reports approximately six million hormone-optimization procedures across its history and approximately 400,000 active patients.^[2]

Those are company-reported scale figures—not six million unique women and not six million current patients.

Biote describes a system built around training, a proprietary dosing algorithm, clinical decision-support software, practice management, inventory support, marketing, mentorship, and approved-vendor requirements. It also earns procedure-based fees from partnered clinics. Biote says the practice of medicine remains the domain of the clinician and warns investors that outcomes may not be consistent across clinicians and clinics.^[2]

The sales pitch reached your clinician first

Both systems are sold to clinicians partly as business opportunities.

That does not make the treatment fake. It does explain why so many clinic pages read like advertisements: the sales pitch was made to your clinician before it was made to you.

The practical response is not cynicism. It is verification. A strong clinician can use a commercial system responsibly. A weak clinician can hide behind an impressive certificate. Your job is to tell them apart before the first insertion.

---

What is similar—and what is not interchangeable?

Both systems sit in the same broad category: custom-compounded subcutaneous hormone pellet therapy delivered through independently practicing clinicians. That does not make their finished pellets equivalent. The exact pharmacy, hormone combination, strength, inactive ingredients, dose, lot, insertion technique, and follow-up plan can differ. Similar category is not interchangeable product.

Point	What is similar	What can differ
Regulatory category	The custom-compounded finished pellets are not FDA-approved	Facility, formula, strength, lot, quality history, and prescription
Hormones used	Clinics may prescribe estradiol and/or testosterone	Which hormone, whether hormones are combined, and exact milligrams
Manufacturing setting	Both systems describe use of FDA-registered 503B outsourcing facilities	The specific facility and its inspection, warning-letter, and recall history
Procedure	A clinician places small pellets under the skin through an in-office insertion procedure	Technique, site, sterile process, aftercare, complication management, and experience
Duration	Published company and clinic claims generally cluster around roughly three to six months	Actual interval by formulation, dose, individual response, and clinician plan
Dose control after insertion	There is no dial, patch to peel off, or pill to skip	Whether early removal is feasible, who performs it, when, at what cost, and with what limitations
Insurance	No brand offers a national guarantee of coverage	Visit, laboratory, procedure, and medication benefits may be handled separately by a specific plan
Decision-maker	A licensed prescriber must evaluate and prescribe	The quality and reasoning of that clinician

A 503B outsourcing facility is not a casual back-room pharmacy. It registers with the FDA, is subject to current good manufacturing practice requirements, reports certain product information, and is subject to FDA inspection.^[5]

But this is the sentence clinic marketing often blurs:

An FDA-registered facility is not an FDA-approved finished drug.

The facility is regulated. The custom-compounded pellet was not put through the FDA's premarket approval process for that finished product's safety, effectiveness, labeling, and manufacturing consistency.

And “bioidentical” does not close that gap. It describes molecular structure; it does not establish that two finished products are equivalent, interchangeable, or equally predictable.

---

Who actually makes your pellet—and can you look them up?

Biote provides the stronger public paper trail, but even a Biote certificate does not identify the maker of an individual pellet. Its 2025 Form 10-K names Asteria Health, AnazaoHealth, and Carie Boyd's as primary 503B facilities while stating that practitioners may use others. SottoPelle's public materials checked through August 25, 2026 did not name its current facility.

What Biote discloses

Biote's 2025 Form 10-K names three primary facilities used by certified practitioners:^[2]

1. Asteria Health in Birmingham, Alabama—owned by Biote since March 18, 2024.
2. AnazaoHealth Corporation.
3. Right Value Drug Stores, LLC, doing business as Carie Boyd's Prescription Shop.

Biote also says:

• certified practitioners may use a variety of outsourcing facilities;
• it does not control or direct the compounding or manufacturing processes at AnazaoHealth or Carie Boyd's; and
• the primary facilities have each received FDA warning letters and Form FDA 483 observations at some point, with Asteria receiving a Form FDA 483 in December 2025.^[2]

That last fact needs proportion, not drama. A Form FDA 483 lists inspection observations; it is not by itself a final agency determination. A historical warning letter does not automatically mean a current product is defective. These records do mean the facility name matters because that is how a patient or clinician checks the relevant regulatory history.

What SottoPelle discloses

SottoPelle's public materials say its pellets are made through an FDA-registered 503B outsourcing facility. Its training materials also refer to clinicians having a choice of pellet provider.^[3]

What we could not find in the first-party materials available through August 25, 2026 was the current facility's name.

They just never say which one.

Why we are not turning this into an accusation

Not naming a supplier is not proof the supplier is worse. SottoPelle is private and does not have Biote's public-company filing obligations. A system that lets clinicians choose among facilities may not have one universal maker to name.

Here is the uncomfortable part, and we would rather say it than score a cheap point:

Biote's disclosure obligations are exactly why you can read about its recall. If a comparable event occurred at an unnamed SottoPelle supplier, finding it would require knowing the supplier's name first.

Transparency is what makes the transparent company look worse in the next section. Hold that in your head while you read it.

The one question that fixes the problem

Ask the clinic:

Which 503B outsourcing facility made the exact pellet you plan to use, and what is the lot number?

Get the answer in writing. If the clinic will not provide a facility name and lot traceability, the brand argument is over. Leave.

---

What happened in the 2026 Asteria hormone-pellet recall?

On January 26, 2026, Asteria Health—Biote's wholly owned 503B facility—voluntarily recalled specific hormone-pellet lots because of potential metal particulate matter. The FDA classified the action as Class II on February 11. The recall did not cover every Biote pellet or every Asteria lot, and an insertion date alone cannot establish exposure.^[1][6]

Recall fact	Verified detail
Recalling firm	F.H. Investments, Inc., doing business as Asteria Health; Biote-owned 503B facility in Birmingham, Alabama
Initiated	January 26, 2026
Reason	Potential presence of metal particulate matter
Shipping window	May 20, 2025–January 19, 2026 in Biote's January 26 Form 8-K; the later 2025 Form 10-K says January 20, 2026
FDA classification	Class II, classified February 11, 2026
Products	Specific estradiol, testosterone, and certain testosterone-combination pellet lots—not every pellet made by Asteria or used by Biote clinics
Scale	FDA enforcement entries collectively listed more than 118,000 estradiol pellets and more than 600,000 testosterone or testosterone-combination pellets
Distribution	Nationwide
Notification	Biote said it notified affected practitioners; the enforcement entries identify letter notification
What date checking can prove	Only whether an insertion occurred during the broad shipment window—not manufacturer, lot, or exposure

The one-day end-date mismatch is in Biote's own filings. We are not quietly choosing one. The first disclosure says January 19; the later annual report says January 20.^[1][2]

What Class II does—and does not—mean

An FDA Class II recall means use or exposure may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse consequences is remote.^[6]

It does not mean “nothing could happen.” It also does not mean serious injury was expected.

The fair reading

A voluntary recall conducted with the FDA's knowledge is the quality system doing what a quality system is supposed to do once a problem is identified. The recall was limited to specified lots. It is not evidence that every Asteria pellet was contaminated, every Biote clinic used Asteria, or every patient treated during the date window received an affected lot.

This was not a cover-up, and we will not describe it as one.

Now the narrow part that affects you:

Affected practitioners received notice. We found no public patient press release from Biote. Whether an individual patient heard about the recall depended on what her clinic did with the letter.

That is why the clinic's recall-notification protocol belongs in your decision before an insertion, not after one.

Were you affected?

If you were implanted between May 20, 2025 and January 20, 2026, ask your clinic:

1. Which facility made my pellets?
2. What were the lot numbers?
3. Were any of those lots included in the Asteria recall?
4. When did the clinic receive the notice?
5. How did the clinic identify and contact affected patients?
6. What follow-up, if any, does the clinic recommend for my specific lot and situation?

A date match is not a diagnosis and not proof of an affected lot. Only the clinic's product records can answer the lot question.

And on the SottoPelle side

We found no recall under the SottoPelle or Tutera Medical names through August 25, 2026. That is worth stating.

It is not enough to declare a cleaner supply record. Without the current supplier name, a supplier-level FDA and recall search remains unresolved. That is the provenance problem landing with real weight—and it lands without accusing anyone of anything.

---

What did the FDA find in Biote's older adverse-event records?

During a 2018 inspection of BioTE Medical, FDA investigators found information on 4,202 adverse events that had not been reported to the agency. That number is serious, but it is routinely misused. The FDA said missing critical information allowed it to attribute only 61 reports—such as pellet extrusion and cellulitis—to compounded testosterone pellets.^[7]

The FDA said the records suggested possible associations with conditions including endometrial cancer, prostate cancer, stroke, heart attack, deep-vein thrombosis, cellulitis, and pellet extrusion. It also said the reports were incomplete.

That distinction matters.

This is not a record of 4,202 proven pellet injuries. It is a record of 4,202 adverse-event reports that the FDA said should have reached the agency, most of which lacked enough information for attribution.

The FDA's account says Carie Boyd's and AnazaoHealth produced the pellets and BioTE marketed them. The event therefore belongs in a Biote comparison because it reveals a real reporting failure around the system. It does not prove that a SottoPelle pellet is safer. It does not prove that every reported condition was caused by a pellet. And it should not be inflated into a number the source does not support.

The practical question is still the same one:

Does your clinic have a written process for documenting, reporting, and following adverse events—and can it explain that process before you pay?

---

Are SottoPelle or Biote pellets FDA-approved?

No. The custom-compounded finished pellets used in SottoPelle and Biote systems are not FDA-approved. The United States has no FDA-approved estradiol pellet for menopausal treatment and no FDA-approved testosterone product for women. Testopel is an FDA-approved testosterone pellet for specified male indications; it is not the custom-compounded product these systems use for women.^[8][9]

Product or route	FDA-approved finished product?	What that means here
Custom-compounded SottoPelle estradiol and/or testosterone pellets	No	Facility registration does not convert the finished pellet into an approved drug
Custom-compounded Biote estradiol and/or testosterone pellets	No	The same rule applies even when the facility is Biote-owned
Testopel testosterone pellets	Yes	Prescription-only Schedule III product labeled for specified male conditions, not an FDA-approved testosterone treatment for women
FDA-approved systemic estradiol patches, gels, sprays, and oral products	Yes	Adjustable alternatives with approved labeling; the right route depends on the person
FDA-approved local vaginal estrogen products	Yes	Used for local genitourinary symptoms; not interchangeable with systemic therapy
FDA-approved micronized progesterone	Yes	One option clinicians may use when endometrial protection is required; the plan is individualized

About the word “bioidentical”

“Bioidentical” describes a hormone with the same chemical and molecular structure as a hormone the body makes. It is not an FDA approval category.

The Menopause Society says many well-tested, FDA-approved hormone products meet that definition. It also says custom-compounded hormones have not been tested to establish safety, effectiveness, absorption, or predictable blood and tissue levels in the way approved products have.^[10]

So the accurate distinction is not “bioidentical versus pharmaceutical.”

It is:

• FDA-approved finished hormone product, with approved labeling and premarket review; versus
• custom-compounded finished product, made for clinical use under compounding law but not approved as that finished drug.

Neither “natural” nor “bioidentical” answers the regulatory question.

Testosterone is a controlled substance

Testosterone is a Schedule III controlled substance in the United States. A testosterone pellet requires a valid prescription from an authorized prescriber, and controlled-substance rules apply regardless of brand or route.^[9]

There is no SottoPelle or Biote shortcut around the prescription requirement. A clinic's questionnaire, lab panel, or dosing software does not replace a prescriber's evaluation.

The FDA-approved comparison is not a moral judgment

An FDA-approved patch is not automatically the right treatment for every woman, and a compounded product is not automatically poor care. Compounding can serve a legitimate patient need when an approved product cannot meet it.

But the burden of explanation changes.

If a clinic recommends a compounded pellet when an adjustable FDA-approved route could meet the same treatment goal, it should be able to tell you why the pellet's tradeoff is worth it for your situation—not just why pellets are convenient for the clinic.

---

How much do SottoPelle and Biote actually cost?

Neither company publishes a national patient price, and local quotes are not comparable until you separate consultation, baseline labs, medication, insertion, first-cycle fees, follow-up labs, membership, and repeat dosing. Our August 25, 2026 clinic snapshot found published amounts from $250 member pricing to $425 per insertion—but those figures do not buy the same bundle.^{[11][12][13][14]}

The four-clinic price snapshot we verified

This is a small, non-random snapshot, not a national average. It contains three Biote clinic pages and one SottoPelle clinic page. It is useful because it shows exactly why a headline price is not enough.

Clinic / system	Published amount	What the page says is included or required	What remains unknown	Verified
Svelte Medical, Orlando / Biote	$150 initial labs; $375 women's procedure; $75 first-time pellet fee; $40 post-labs without thyroid or $62 with thyroid	The page itemizes these charges separately	Any separately billed consultation, membership, supplements, complication care, and later timing	August 25, 2026
Robinson Wellness, St. Petersburg / Biote	$410 per procedure; page says most women return every 3–4 months	Procedure amount and stated interval	Labs, consultation, first-cycle fees, and why the page's stated $1,500–$1,800 annual estimate exceeds straight 3–4 procedure arithmetic	August 25, 2026; clinic labels price September 2025
EBO MD, Missouri / Biote	$250 current member price for women; usually about every four months	Member price and timing claim	Membership cost and terms, labs, consultation, first-cycle fees, and nonmember price	August 25, 2026
Austin Labiaplasty / SottoPelle	$425 per insertion for its listed SottoPelle testosterone therapy	Page says consultation and labs are required before treatment	Consultation and lab prices, whether the amount changes with formulation or dose, and follow-up charges	August 25, 2026

The arithmetic the clinic page does not do for you

On Svelte's published list, the visible first-cycle components add to:

• $150 initial labs
• $375 women's procedure
• $75 first-time pellet fee
• $40 post-labs without thyroid or $62 with thyroid

That is $640 or $662 if every listed component applies. It is not a universal Biote first-cycle price. It is reproducible arithmetic from one clinic's page, before any separately billed service not shown in those line items.

Robinson Wellness publishes $410 per procedure and says women commonly return three to four times a year. Straight multiplication gives $1,230–$1,640. The same page states an annual estimate of $1,500–$1,800. The difference may reflect additional assumptions, but the page does not reconcile them. We therefore publish the components and the arithmetic rather than pretending the higher total is self-explanatory.

This is the original price finding that matters:

Your quote is not one number.

A clinic advertising $250 can cost more than one advertising $425 if the lower figure requires a membership or excludes labs, consultation, first-cycle fees, follow-up, and supplements. Two clinics quoting the same procedure price can still differ by hundreds of dollars.

Ask for this itemization before paying

Your written quote should answer all of these:

1. Consultation or evaluation fee
2. Baseline laboratory cost
3. Whether labs can be billed through insurance separately
4. Pellet medication cost
5. Insertion procedure cost
6. First-cycle or “new patient” surcharge
7. Follow-up laboratory cost and timing
8. Required membership cost and minimum term
9. Required or strongly promoted supplements
10. Expected reinsertion interval used for the 12-month estimate
11. Cost of an unscheduled visit for side effects
12. Cost and policy for attempted early removal
13. Refund or credit policy if treatment is postponed or cancelled

Is one brand cheaper?

We cannot support a brand-level price winner.

We have a current itemized Biote example, two additional Biote price pages, and one SottoPelle insertion price. We do not have a matched multi-market sample with the same inclusions. Anyone naming a national winner from that evidence is guessing.

Not sure pellets are worth the first-year cash commitment for your situation? Get your personalized HRT action plan with Find My HRT Path before you book a pellet consult.

---

What if the dose is wrong—can a hormone pellet be removed?

A pellet dose cannot be dialed down after insertion, and routine, simple, on-demand removal is not the standard escape route. Early removal may require another procedure and depends on timing, location, clinician skill, and clinic policy. That loss of reversibility is one reason ACOG recommends other delivery forms for testosterone.^[15]

This is the section that changes minds, so we will be plain about it.

Once it is in, there is no dial. No patch to peel off. No pill to skip. The current implant keeps releasing hormone while it remains active.

The absolute claim “pellets cannot be removed” is too broad. The FDA-approved Testopel label says that, if testosterone's effects must be discontinued because of complications, the pellets would have to be removed. It also warns that pellet implantation is much less flexible for dosage adjustment than oral or injected products.^[9]

That does not mean removal is easy, immediate, complete, or available from the clinic that inserted it.

A pellet can be difficult to locate after insertion. Removal can require an incision and tissue dissection. Feasibility may change as the pellet dissolves. Some clinics do not offer removal at all. Some may refer out. The answer has to come from the clinic in writing.

Do not accept “we can always take it out”

Ask:

• Who performs the removal?
• At what point after insertion is it realistically possible?
• How is the pellet located?
• Is every pellet expected to be retrievable?
• Where is the procedure done?
• What are the scar, bleeding, infection, and incomplete-removal risks?
• What does it cost?
• Has this clinician actually removed one?
• What happens if removal is not feasible?

A vague “we would manage your symptoms” is not a removal policy.

The stopping-rule mismatch

Clinical guidance on testosterone for women often frames treatment as a monitored trial. The Endocrine Society suggests stopping therapy if there is no response by six months.^[16]

With a patch or gel, “stop” can mean no next dose. With a pellet, declining the next insertion stops future exposure—but it does not switch off the pellet already implanted.

That is the mismatch almost nobody names:

A stop rule assumes the route can stop. A live pellet cannot be switched off.

This is not automatically a dealbreaker. Some women deliberately choose fewer dosing events and accept the reduced control. It is a dealbreaker when the clinic sells convenience without spelling out what happens if the dose overshoots or the treatment is simply wrong for you.

The Decision Resolution Point

If the sentence that stopped you was “there is no dial,” that is a completely reasonable place to change routes.

Compare adjustable care before you pay for an implant:

• Midi vs Biote: adjustable online menopause care versus pellets
• Winona vs Biote: online HRT versus pellet therapy
• Testosterone pellets vs cream for women

A visit is an evaluation, not a promise of a prescription.

---

How long do SottoPelle and Biote pellets last?

There is no verified brand-wide duration that applies to every woman. SottoPelle currently advertises four to six months, while individual Biote clinic pages commonly publish roughly three to four months or about four months. Formulation, dose, activity, individual response, and clinic protocol can change the reinsertion interval.^[4][12][13]

The draft version of this comparison treated “three to four months” as identical across brands. That was too neat.

SottoPelle's homepage says treatments last four to six months. Robinson Wellness says most women return for Biote insertion every three to four months. EBO MD says women are usually dosed about every four months.

Those are company and clinic claims, not a head-to-head duration study.

The right budgeting question is not “How long does the brand last?” It is:

What interval does this clinician expect for my exact formulation and dose, and what happens to the 12-month cost if I need one extra insertion?

Ask the clinic to calculate both:

• expected year-one cost at the planned interval; and
• year-one cost with one additional insertion and follow-up panel.

That one extra line is where a reassuring annual estimate often breaks.

---

Which is safer, SottoPelle or Biote?

No evidence establishes either brand as safer. The stronger evidence question is pellets versus other routes, compounded versus FDA-approved finished products, and one clinic's dosing and follow-up versus another's. ACOG, The Menopause Society, and the global testosterone consensus all raise concerns about compounded therapy, supraphysiologic exposure, missing safety data, and pellet irreversibility.^[10][15][17]

We are going to give you both sides because the pellet case is not imaginary.

The evidence hierarchy is the problem.

What major guidance says

ACOG: compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist. On testosterone pellets, ACOG cites the lack of safety data and inability to remove the pellet and recommends other preparations.^[15]

The Menopause Society: custom-compounded hormones are not established as safer or more effective than approved products and have not been tested to prove predictable absorption or tissue levels.^[10]

Global Consensus Position Statement on testosterone therapy for women: the only evidence-based indication is properly diagnosed hypoactive sexual desire disorder in postmenopausal women after formal assessment. The statement says its recommendations do not apply to injectables, pellets, compounded preparations, or formulations that produce supraphysiologic concentrations, and it does not recommend compounded testosterone when an authorized equivalent is available.^[17]

Those statements are not saying every woman who uses a pellet will be harmed. They are saying the evidence supporting broad claims is not strong enough to erase the route's tradeoffs.

What the adverse comparative study found

A 2021 retrospective chart review compared 384 women receiving pellet hormone therapy with 155 women receiving FDA-approved hormone therapy. It reported:^[18]

• overall side effects in 57.6% of the pellet group versus 14.8% of the FDA-approved group;
• among women with an intact uterus, abnormal uterine bleeding in 55.3% versus 15.2%;
• hysterectomy during follow-up in 20.3% versus 6.3%; and
• higher peak estradiol and testosterone concentrations in the pellet group.

Those are serious findings. They are also observational findings, not randomized proof that the pellet route alone caused every difference.

The comparison groups did not receive identical hormones or doses. The pellet group was far more likely to receive testosterone, which complicates any attempt to label every androgenic effect a route effect. That limitation belongs beside the numbers, not buried after them.

What the supportive comparative study found

A 2025 retrospective, single-practice study compared 200 women started on compounded estradiol-plus-testosterone pellets with 204 started on a compounded estradiol-plus-testosterone lotion.^[19]

Among women reached for longer-term follow-up, the paper reported:

• continuation of the initiated route in 76% of pellet patients versus 59% of lotion patients;
• 89% of pellet patients versus 78% of lotion patients saying HRT treated their symptoms; and
• no significant difference in reported adverse symptoms between groups.

That is legitimate evidence in favor of the pellet route's acceptability in that practice.

It is not a randomized trial. Patients and the prescriber selected treatment. It was a single clinician's practice. The comparator was another compounded formulation—not an FDA-approved estradiol patch—and only about half the eligible cohort completed the long-term questionnaire.

The study supports “some women stay on and report benefit from pellets.” It does not prove SottoPelle beats Biote, that pellets beat an FDA-approved patch, or that the route has settled long-term safety.

What the small 2025 testosterone-pellet study found

A 2025 observational study followed 31 women across two testosterone-pellet dose groups—19 women receiving 75 mg and 12 receiving 100 mg—covering 220 insertions.^[20]

The study reported no statistically significant rise in hematocrit or blood pressure across the observed insertions. In the 75 mg group, one woman reported new facial hair and two reported vaginal bleeding. The 100 mg group reported no listed adverse effects, although two women began antihypertensive medication during follow-up.

That is useful, narrow evidence. It is also a tiny sample with no randomized comparator. It cannot carry a broad “minimal side effects” promise for every woman or every dose.

What can go wrong in practice

The risks and failure points a clinic should discuss include:

• dose that produces unwanted androgenic or estrogenic effects;
• abnormal uterine bleeding;
• acne or increased facial/body hair;
• scalp-hair changes;
• mood or sleep changes;
• breast tenderness or fluid retention;
• pellet extrusion;
• insertion-site infection, bruising, bleeding, scarring, or pain;
• delayed correction because the dose cannot be dialed down;
• inadequate endometrial protection when systemic estrogen is used in a woman with a uterus;
• loss of manufacturer or lot traceability;
• missed recall or adverse-event communication.

This is not a prediction that these will happen. It is the list your consent conversation should be able to survive.

The honest conclusion

This page cannot tell you which pellet brand is better. Anyone who tells you they can is selling certainty the evidence does not contain.

No randomized trial has compared SottoPelle with Biote. No trial establishes a brand-level safety winner. The evidence in favor of pellets is mostly observational and practice-based. The evidence against them includes observational safety signals and consistent guideline concerns about compounding and reversibility.

That does not make the answer useless.

It makes the answer actionable:

If the brands cannot be separated on clinical evidence, stop comparing logos. Compare the clinician's source, dose, consent, follow-up, uterine-protection plan, recall protocol, and response to a bad outcome.

---

Which one has more providers near you?

Biote publishes the clearer current scale figure: more than 9,200 trained providers in more than 5,300 partnered clinics as of December 31, 2025. SottoPelle publishes three figures with different scopes—1,200+ trained and certified worldwide, 3,000+ trained across the United States, and 3,500+ trained over time—so a clean active-network comparison is not possible.^[2][4]

The innocent explanation is probably the right one: trained, certified, currently active, and ever trained are different counts.

Someone trained years ago who no longer practices may remain in a lifetime total. A clinician may complete training without appearing as an active certified provider. A worldwide certified count and a U.S. trained count are not denominators you can place side by side.

Biote's scale figures have their own limit. Approximately six million procedures is not six million unique patients. One person can receive repeated procedures over years.

So ignore the seductive national arithmetic and run the local test:

1. Is the clinician's license active and unrestricted?
2. Is the certification current?
3. How many pellet insertions did this clinician personally perform in the last 12 months?
4. How many were in women with a situation like yours?
5. Which exact facility and lot will be used?
6. Who handles complications and early-removal requests?
7. What happens if the clinic stops participating in the brand system?
8. How are records transferred if you switch?

High procedure volume can signal experience. It is not a substitute for safe selection, good consent, dose discipline, or a real complication plan.

A high-volume clinician who gets vague about the lot number is not the winner. Neither is a low-volume clinician hiding behind a national network statistic.

---

Does insurance cover SottoPelle or Biote?

There is no national promise that a SottoPelle or Biote pellet program will be covered. Biote tells investors that third-party reimbursement is not typically available for the Biote Method. A plan may still adjudicate the evaluation, laboratory work, medication, and insertion procedure separately, so the answer must come from written benefit verification—not the clinic's general assurance.^[2]

The draft said compounded pellets lack “the drug code an insurer needs.” That was too absolute. Coverage and coding vary, and one code does not decide every claim.

Separate the bill into four questions:

1. Will the plan cover the clinician visit?

Possibly, depending on the clinician's network status, the billed service, the diagnosis, and the plan. An insurance-accepting office can still run pellet therapy as a separate cash service.

2. Will the plan cover the laboratory work?

Possibly. Ask whether the clinician can send the order to an in-network laboratory instead of bundling it into a cash package.

This is the question that can save real money without changing treatment:

Can my baseline and follow-up labs be billed through my insurance separately, and which laboratory will you use?

3. Will the plan cover the compounded pellet and insertion?

Do not assume it. Ask the clinic for the exact billing codes it intends to use, then ask the insurer for a written benefit response. “We provide a superbill” is not the same as “your plan reimburses this.”

4. Can HSA or FSA funds be used?

A prescribed medical expense may qualify, but account rules and documentation requirements apply. Confirm with the plan administrator rather than treating a clinic's “HSA accepted” logo as tax advice.

The insurance checklist

Before paying, get:

• the clinician's network status;
• the laboratory name and network status;
• the exact cash-pay items;
• the procedure and diagnosis codes the clinic expects to submit, if any;
• whether prior authorization is attempted;
• whether the clinic submits claims or gives you an itemized receipt;
• the cancellation/refund rule if insurance rejects a related service; and
• a written 12-month cash maximum based on the expected insertion interval.

If medication coverage is non-negotiable, pellets may be the wrong route. Compare an FDA-approved, adjustable option through a provider model built around insurance before paying cash for an implant.

---

Can you switch between SottoPelle and Biote?

Yes, a new qualified prescriber can evaluate you after treatment under either system, but switching is not a simple brand transfer. The new clinician needs the exact insertion date, hormones and milligrams, manufacturer, lot, symptoms, recent labs, medication list, and uterine-protection plan. Timing and new testing should be decided clinically, not by a generic three-month rule.

Bring:

• your last insertion date;
• the exact dose in milligrams for each hormone;
• the compounding facility;
• the lot number;
• your recent laboratory results;
• your current prescription and supplement list;
• any adverse effects or bleeding history;
• any procedure or infection records; and
• the plan used to protect the uterine lining if you have a uterus and received systemic estrogen.

Do not accept “three pellets” as a transferable dose description.

Different facilities can make different strengths. Three pellets at one clinic may not equal three pellets at another.

Ask for milligrams, not pellets. Milligrams travel; pellet counts don't.

The new clinician may want new labs or may use recent results. The timing depends on what was implanted, when, your symptoms, the planned route, and the clinician's judgment. Do not stack a new dose on top of a live pellet or switch routes without a prescriber-directed plan.

Settle this before booking:

Will the new clinic accept and review my existing records before charging for a new treatment package?

That is a care-quality question and a cancellation-friction question at the same time.

---

Where do other pellet brands—and the “Biote lawsuit”—fit?

EvexiPEL, Pellecome, Pro-Pell, Purepell, and pharmacy-led protocols also exist. The same decision rule applies: a brand or certification does not replace the exact facility, lot, dose, consent, follow-up, and complication plan. This article does not rank those systems because that would create a different comparison and require a separate, current evidence set.

About the “Biote lawsuit” search results

Biote's public filings describe multiple legal matters over time. One prominent 2024 matter was a founder-and-shareholder dispute with Gary Donovitz that ended in a settlement and stock repurchase. That was a corporate dispute, not proof that a patient was injured by a pellet.^[21]

That correction has a limit.

It would also be wrong to declare that no patient claim, product-liability allegation, or other proceeding has ever existed anywhere. Attorney lead-generation pages are not reliable evidence of liability, but a corporate settlement is not a universal clearance certificate either.

For a treatment decision, the stronger evidence is:

• FDA records;
• the exact facility's inspection, warning-letter, and recall history;
• peer-reviewed clinical evidence;
• professional guidance;
• your clinic's consent and adverse-event process; and
• the facts of any specific adjudicated case—not a search-ad headline.

---

What should you ask before you pay? The 12-question pellet clinic test

Because neither brand publishes a national patient price and neither certificate identifies the full treatment plan, the decisive questions are the ones only your clinic can answer. These twelve establish provenance, dose, medical rationale, real cost, reversibility, uterine protection, monitoring, recall communication, and clinician experience before money or medication changes hands.

Print this. Take it in. Do not pay until the blanks are filled.

#	Ask this	A strong answer sounds like
1	Which FDA-registered 503B outsourcing facility makes the exact pellets you use?	A specific legal company name and city, given without hesitation
2	What is the lot number, and where will it appear in my record?	They can show the packaging or explain the traceable record before insertion
3	What hormones, formulation, strength, and dose in milligrams are you prescribing?	A number for each hormone—not “two pellets” or “the female dose”
4	How did you arrive at that dose, and what baseline information changed the decision?	A walkthrough of your history, symptoms, examination when relevant, labs, and the limits of the dosing tool
5	Why is a pellet a better fit for me than an adjustable FDA-approved route?	A patient-specific tradeoff, not “pellets are natural” or “everyone feels better”
6	What is the total amount due today, line by line?	Consultation, labs, medication, insertion, first-cycle fee, membership, and anything else itemized
7	What is the expected 12-month total, and what assumptions are behind it?	A written total showing the expected interval and the cost with one extra insertion
8	What is your written plan if the dose is too high or I want it removed?	Who evaluates, who can remove it, practical limits, location, risks, and cost
9	I do / do not have a uterus. What is my endometrial-protection plan if I receive systemic estrogen?	A clear, individualized answer in the treatment plan—not a supplement pitch
10	When is follow-up, what will you monitor, and what finding would change the next dose?	A date, clinical targets, symptom review, and an action plan
11	How will you contact me about a recall or safety notice?	A documented process tied to lot records and current contact details
12	Is your license and certification current, how many insertions did you perform in the last year, and who handles complications?	Verifiable credentials, a credible volume, and named responsibility after the procedure

Question 9 is not optional

If you have a uterus and receive systemic estrogen, the clinician must address endometrial protection. A clinic that cannot give you a clear plan before insertion is not ready to treat you.

Questions 1, 8, and 11 are the character test

They force the clinic to talk about what happens when the polished outcome does not happen.

A strong clinic does not promise perfection. It proves traceability, explains the limits of removal, and knows how it would reach you after a recall.

A weak clinic changes the subject.

Take the 12-question card to the consult. Do not pay until the blanks are filled.

Still unsure whether pellets are even the right lane? Use Find My HRT Path first. It routes by symptoms, age, uterus status, treatment preference, state, risk history, and coverage—and flags when in-person care is the better starting point.

---

So which should you choose?

If you have decided on pellets, choose the clinician who can identify the facility and lot, justify the exact milligrams, disclose the complete 12-month cost, explain endometrial protection, and put the side-effect, removal, and recall plan in writing. If one clinic cannot do that, its logo does not deserve a second round of consideration.

If you…	Then…
Already have a trusted clinician who answers all 12 questions	The brand becomes secondary. Verify the facility, lot, dose, and plan and decide with that clinician
Want the stronger public supply-chain paper trail	Lean toward the better Biote clinic, while still asking which facility made your exact pellet
Are choosing between two unfamiliar clinics	Choose on clinical reasoning, traceability, consent, follow-up, and complication responsibility—not the certificate
Have a uterus and no clear protection plan with systemic estrogen	Stop. Settle question 9 before any insertion
Need to change or stop the dose within days	Pellets are the wrong route for that priority
Need predictable medication coverage	Verify benefits first or compare an FDA-approved route designed around insurance
Have not discussed FDA-approved adjustable options	Discuss them before accepting an irreversible-for-the-moment route
Were implanted during the May 20, 2025–January 20, 2026 Asteria shipment window	Call the clinic for the facility and lot; the date alone does not prove exposure
Feel rushed by a package deadline	That is a sales deadline, not a hormone emergency
Get vague answers about the pharmacy, lot, dose, or removal	Leave. The answers will not improve after the insertion

How pellets compare with adjustable routes

Pellets trade fewer dosing events for less control. That convenience is real, and dismissing it is condescending. Some women do not want a daily gel, a recurring patch change, or a pill schedule.

What the pellet gives up is also real: immediate dose adjustment, easy discontinuation, a standardized FDA-approved finished product, and—in many cases—more straightforward insurance handling.

Systemic estradiol patches, gels, sprays, and oral products are not the same as local vaginal estrogen. A local product treats local genitourinary symptoms; a systemic route addresses systemic treatment goals. The route has to match the problem.

If convenience is your highest priority and the clinic passes the 12-question test, a pellet may still fit your values. If control, adjustability, approved labeling, or predictable coverage is the priority, it probably does not.

---

How we compared SottoPelle and Biote

This comparison follows The HRT Index Verification Standard: we read every published price we use, separate FDA-approved from compounded products, verify supply-chain and access claims against current sources, and date the verification. We assess the page through five pillars in this exact order: clinical legitimacy, care quality, medication fit, price transparency, and access.

Pillar	SottoPelle	Biote
Clinical legitimacy	Company-stated: clinician certification, Dosaggio, and use of 503B supply. Independently verified: the custom-compounded finished pellets are not FDA-approved. Unresolved: current supplier identity and supplier-level regulatory history.	Company-stated: training, proprietary decision support, and approved-vendor framework. Independently verified: three primary 503B facilities are named; Asteria is owned; the 2026 recall affected specific Asteria lots. Unresolved: the facility and lot used by any individual clinic until the clinic discloses them.
Care quality	Company-stated: one-day certification, required modules, insertion training, and Dosaggio access. Independently verified: public training details. Unresolved: consultation depth, follow-up, complication response, and outcome consistency by clinic.	Company-stated: curriculum, mentorship, clinical decision support, and practice systems. Independently verified: network and training disclosures in the Form 10-K. Unresolved: consultation depth, follow-up, complication response, and outcome consistency by clinic.
Medication fit	Custom-compounded estradiol and/or testosterone may be used. Exact formula, dose, facility, and uterine-protection plan are clinic-specific.	Same broad category, but exact facility, formula, dose, and lot can vary. Testosterone remains Schedule III and requires a valid prescription.
Price transparency	Verified: no national patient price found. One current clinic page lists $425 per insertion and says consultation and labs are required without pricing them.	Verified: no national patient price found. Three current clinic pages show materially different structures: itemized first-cycle charges, per-procedure pricing, and member pricing.
Access	Company-stated: 1,200+ trained and certified worldwide, 3,000+ U.S. trained, and 3,500+ trained over time. Unresolved: a current active-clinic denominator.	Company-stated in SEC filing: 9,200+ providers in 5,300+ clinics as of December 31, 2025. Unresolved: whether the nearest listed clinic is active, accepting patients, and strong on the 12 decision questions.

We do not publish a numeric score or star rating because the evidence does not support pretending these systems can be reduced to one precise number.

What we did

We reviewed:

• Biote's 2025 Form 10-K and January 26, 2026 Form 8-K;
• FDA materials on compounded products, adverse-event reporting, recall classification, and menopause hormone products;
• the Testopel prescribing information;
• SottoPelle's current public training, provider-count, duration, and pricing-page materials;
• four named clinic price pages;
• ACOG guidance;
• The Menopause Society's current patient guidance;
• the Global Consensus Position Statement on testosterone for women;
• the 2021 adverse comparative study;
• the 2025 pellet-versus-compounded-lotion study; and
• the 2025 small testosterone-pellet observational study.

What we did not do

We did not:

• treat a company claim as independent proof;
• convert a 503B registration into FDA approval;
• assume the brand identifies the individual facility or lot;
• infer a national price from four clinics;
• publish a price winner from an unmatched sample;
• use an anonymous review as medical or safety evidence;
• call 4,202 reports 4,202 proven injuries;
• claim that a pellet is impossible to remove under every circumstance; or
• manufacture a winner where no head-to-head trial exists.

---

What we actually verified—and what we could not

Verified through August 25, 2026: Biote's three primary 503B facilities, Asteria ownership, practitioner choice of facilities, network scale, and company-stated procedure count · the January 2026 recall window and the one-day filing discrepancy · the FDA Class II definition · the FDA's 2019 account of 4,202 unreported adverse-event records and 61 attributable reports · SottoPelle's current training format, Dosaggio description, provider-count language, and duration claim · four clinic price pages · FDA approval status · testosterone's Schedule III status · guideline wording · the three studies summarized above.

Could not verify—and are telling you instead of guessing:

• the name of SottoPelle's current 503B supplier from its public materials;
• the exact supplier and lot used by a specific SottoPelle or Biote clinic without that clinic's record;
• an active, apples-to-apples national provider count for SottoPelle;
• a matched SottoPelle-versus-Biote national price sample;
• any national promise of insurance coverage;
• a universal clinic cancellation, refund, removal, or adverse-event policy;
• whether a specific patient received a recalled lot from insertion date alone; or
• a head-to-head clinical winner.

Prices, clinic participation, facility relationships, policies, and regulatory records can change. The “Last verified” date changes when those underlying facts are rechecked—not because a sentence was edited.

Disclosure: As of August 25, 2026, The HRT Index has no commercial relationship with SottoPelle, Biote, Tutera Medical, Asteria Health, or the pellet clinics named here. The HRT Index may earn a commission from some telehealth providers reached through linked comparison pages, at no extra cost to you. It did not change the findings on this page. See our affiliate disclosure.

---

SottoPelle vs Biote: frequently asked questions

Is SottoPelle better than Biote?

No evidence establishes SottoPelle as better. No head-to-head study compares the two systems. SottoPelle names its Dosaggio dosing platform and publishes a one-day training structure, while Biote provides more public supply-chain and network disclosure. Choose the stronger clinician and verified treatment plan, not a claimed brand winner.

Is Biote better than SottoPelle?

No evidence establishes Biote as clinically better. Biote has the clearer public paper trail and a much larger company-reported network, but the exact facility, formulation, dose, and clinic quality still vary. Its Asteria facility also had specific pellet lots recalled in 2026.

Are Biote pellets FDA-approved?

No. The custom-compounded finished pellets used through Biote-certified clinics are not FDA-approved. Biote's named primary facilities are FDA-registered 503B outsourcing facilities, but facility registration is not product approval.

Are SottoPelle pellets FDA-approved?

No. The custom-compounded finished pellets used through SottoPelle-certified clinics are not FDA-approved. SottoPelle says its supply comes through a 503B outsourcing facility, but we did not find the current facility name in the public materials reviewed.

What is the biggest difference between SottoPelle and Biote?

The clearest verified difference is public transparency. Biote's SEC filings identify three primary 503B facilities, while SottoPelle's public materials do not name its current supplier. SottoPelle highlights Dosaggio and its training heritage; Biote highlights scale, software, mentorship, and practice support.

Was there a Biote pellet recall?

Yes. On January 26, 2026, Asteria Health—Biote's wholly owned 503B facility—recalled specific hormone-pellet lots over potential metal particulate matter. The FDA classified the recall Class II on February 11, 2026. It did not cover every Biote pellet or every Asteria lot.

How do I know whether my pellet was recalled?

Ask the clinic for the manufacturer and lot number. An insertion date between May 20, 2025 and January 20, 2026 only places the treatment inside the broad Asteria shipment window; it does not establish that Asteria made your pellet or that your lot was recalled.

Did the FDA find 4,202 Biote pellet injuries?

No. The FDA found information about 4,202 adverse events during a 2018 BioTE inspection that had not been reported to the agency. The FDA said critical information was missing and attributed only 61 reports, such as extrusion and cellulitis, to compounded testosterone pellets. The reporting failure is real; “4,202 proven injuries” is not.

How much do SottoPelle and Biote pellets cost?

Neither brand publishes a national patient price. In our small August 2026 clinic snapshot, visible published amounts ranged from a $250 Biote member price to a $425 SottoPelle insertion, but the inclusions differed. Ask for consultation, labs, medication, procedure, first-cycle fees, membership, follow-up, and expected 12-month total separately.

Can hormone pellets be removed?

They may be surgically removable in some circumstances, but removal is not a simple guaranteed on-demand reversal. Feasibility depends on timing, location, clinician skill, and clinic policy. Ask who removes them, what it costs, and what happens when removal is not feasible before insertion.

How long do hormone pellets last in women?

Published claims vary. SottoPelle currently says four to six months; individual Biote clinic pages commonly say roughly three to four months or about four months. Your exact interval depends on the formulation, dose, response, and clinician plan.

Does insurance cover SottoPelle or Biote?

Do not assume it. Biote says third-party reimbursement is not typically available for its method. A plan may handle the visit, labs, medication, and procedure separately. Get the codes and a written benefit response before paying.

Can I switch from Biote to SottoPelle—or the other way around?

A new qualified prescriber can evaluate you, but bring the exact hormones and milligrams, insertion date, manufacturer, lot, recent labs, medication list, and uterine-protection plan. Do not describe the dose only by pellet count and do not overlap treatment without a clinician-directed plan.

Does ACOG recommend testosterone pellets?

ACOG recommends preparations other than pellets for testosterone delivery because of missing safety data and the inability to remove the pellet easily. It also says compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist.

Is testosterone in hormone pellets a controlled substance?

Yes. Testosterone is a Schedule III controlled substance in the United States and requires a valid prescription from an authorized prescriber. The requirement does not disappear because the product is compounded or inserted in a clinic.

Do I need progesterone if I have a uterus and receive estradiol pellets?

If the pellet produces systemic estrogen exposure and you have a uterus, the clinician must address protection of the uterine lining. The exact prescription is individualized, but a vague or missing plan is a reason to stop before insertion.

Who makes SottoPelle's pellets?

SottoPelle's public materials reviewed through August 25, 2026 describe use of an FDA-registered 503B outsourcing facility but do not name the current facility. Ask the clinic for the legal facility name, city, and lot number in writing.

Is there a Biote lawsuit?

Biote has disclosed legal matters, including a founder-and-shareholder dispute settled in 2024. That corporate matter is not evidence of a patient injury. Evaluate any other lawsuit claim from the actual complaint, court record, outcome, and FDA evidence—not an attorney advertisement headline.

---

Still not sure which HRT program is right for you? Take our free 90-second matching quiz.

→ Find My HRT Path

---

Sources

¹ Biote Corp., Form 8-K, January 26, 2026; Biote Corp., 2025 Form 10-K.

² Biote Corp., 2025 Form 10-K.

³ SottoPelle clinician training and certification.

⁴ SottoPelle hormone-therapy training; SottoPelle homepage.

⁵ FDA: Information for outsourcing facilities.

⁶ FDA recall definitions; FDA Enforcement Reports, Asteria Health event 98344.

⁷ FDA statement on adverse-event reporting for compounded drugs, September 9, 2019.

⁸ FDA: Menopause; FDA: Testosterone information.

⁹ DailyMed: Testopel prescribing information.

¹⁰ The Menopause Society: Hormone therapy.

¹¹ Svelte Medical: Biote pricing in Orlando.

¹² Robinson Wellness: Cost of Biote pellets for women.

¹³ EBO MD: Biote hormone-replacement pellets.

¹⁴ Austin Labiaplasty: Procedure pricing.

¹⁵ ACOG Clinical Consensus: Compounded Bioidentical Menopausal Hormone Therapy.

¹⁶ Endocrine Society clinical practice guideline: Androgen Therapy in Women.

¹⁷ Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

¹⁸ Jiang et al., Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy, Menopause, 2021.

¹⁹ Bailey and Rothenberger, Comparison of Two Delivery Methods of Bioidentical Hormone Replacement Therapy, 2025.

²⁰ Hernandez et al., Long-term testosterone pellet insertion in women with low libido, 2025.

²¹ Biote Corp., 2025 Form 10-K—legal proceedings and founder settlement disclosures.

---

This page is editorial research from The HRT Index. It is not medical advice and has not been reviewed by a clinician. Talk with a qualified healthcare professional about your situation before starting, changing, or stopping treatment. FDA-approved and compounded options are labeled separately throughout; custom-compounded products are not presented as equivalent to FDA-approved medication.